Conclusively, we contribute to FLT3-ITD+ AML research by evaluating new TKI compounds for future treatment and by supporting the concept that combinatorial treatments are a solution to enhance drug efficacy, preventing potential resistance mechanisms. The gene discussed is FLT3; the disease is acute myeloid leukemia.